Express Pharma

MARCH 31, 2025

This is different from traditional chemotherapy which is usually given orally and intravenously. Researchers completed phase 1 clinical trials demonstrating safety and tolerance to NEO100 in 2019.

Chemotherapy 66

Chemotherapy 66

Pharmaceutical Technology

APRIL 21, 2023

The FDA previously accepted Daiichi Sankyo’s New Drug Application (NDA) for priority review as a potential treatment for TL3-ITD positive AML used alongside standard cytarabine and anthracycline induction and cytarabine consolidation chemotherapy in October 2022. months in patients on standard chemotherapy, per a June 2022 press release.

Chemotherapy 98

Chemotherapy 98

Pharmaceutical Technology

AUGUST 8, 2022

The treatment is indicated for patients who have previously received chemotherapy in the metastatic setting or recurred during or within six months of receiving adjuvant chemotherapy. months for the chemotherapy arm. months in the chemotherapy arm, indicating a 36% decline in death risk. months compared with 5.1

Chemotherapy 105

Chemotherapy Labelling 105

pharmaphorum

JANUARY 3, 2023

Over recent years, there has been a growing consensus that using chemotherapy and aggressive treatments towards the end-of-life should be avoided, where possible, due to the lower quality of life reported. Once no cure can be found for a patient’s condition, decisions must be made about what is the most suitable path forwards.

Chemotherapy 105

Chemotherapy Immunization Immunity Hospitals 105

pharmaphorum

DECEMBER 8, 2021

China’s Shanghai Henlius Biotech says its experimental PD-1 inhibitor serplulimab has extended survival when added to chemotherapy in a phase 3 trial as first-line therapy for extensive stage small cell lung cancer (ES-SCLC), setting up regulatory filings.

Chemotherapy 98

Chemotherapy 98

Big Molecule Watch

MAY 22, 2023

According to the press release, FYLNETRA—Amneal’s third biosimilar launch in the United States since late last year—is used to treat neutropenia (low neutrophils, a type of white blood cell that fights infection) which is commonly experienced by patients undergoing chemotherapy.

Biosimilars 72

Biosimilars Chemotherapy 72

pharmaphorum

MAY 10, 2022

The two companies have been working together since 2019 on digital health interventions to provide support to people with cancer, focusing initially on tools for patients undergoing cancer immunotherapy.

Chemotherapy 137

Chemotherapy Communication 137

pharmaphorum

JULY 21, 2022

Keytruda has been approved since 2016 as a second-line option after chemotherapy for patients with more advanced disease, i.e. recurrent or relapsed HNSCC that has metastasised to other parts of the body.

Chemotherapy 98

Chemotherapy 98

pharmaphorum

OCTOBER 25, 2021

The European Commission has cleared Keytruda (pembrolizumab) in combination with chemotherapy as a first-line treatment for locally recurrent, unresectable or metastatic TNBC involving tumours with a PD-L1 expression score of 10 or more. months to 23 months, according to data reported at this year’s ESMO cancer conference.

Chemotherapy 87

Chemotherapy Labelling 87

pharmaphorum

FEBRUARY 11, 2022

.” Hopes were high that a drug developed by Sangamo based on its zinc finger nuclease (ZFN) genome-editing technology could lead to the first therapy that could correct the genetic defect n MPS I, but that candidate – called SB-318 – flunked out in a clinical trial reported in 2019 and was discontinued.

Chemotherapy 111

Chemotherapy Drug Development 111

European Pharmaceutical Review

JULY 5, 2022

The availability of oral chemotherapy treatments would provide stomach cancer patients with the option of more efficacious drugs with improved tolerability in a more convenient dosage format” The poor clinical outcomes of stomach cancer make it a key target for drug development. Benefits of daily oral chemotherapy over IV.

Chemotherapy 104

Chemotherapy Dosage Labelling Compounding 104

pharmaphorum

JUNE 8, 2021

Chemotherapy still accounted for 72.6% of the oncology market in China in 2019, compared to 17.1% million in 2019, and are estimated to increase to 5.7 Chemotherapy still plays a significant role in oncology treatment, accounting for 72.6% of the oncology market in China in 2019, compared to 17.1% million in 2030.

Chemotherapy 105

Chemotherapy Pharmaceutical Companies Pharmaceutical Companies Immunization 105

Pharmaceutical Commerce

JANUARY 19, 2024

Today's approval amends the accelerated approval granted by the FDA in April 2019 to Balversa (erdafitinib) for patients with metastatic urothelial carcinoma with susceptible FGFR2 or FGFR3 alterations following prior treatment with platinum-containing chemotherapy.

Chemotherapy 52

Chemotherapy 52

pharmaphorum

NOVEMBER 3, 2021

Around one in five gastric cancers are HER2-positive, opening up a new market for AZ and Daiichi Sankyo, which have been collaborating on Enhertu since signing a multi-billion partnership for the drug in 2019. billion licensing deal.

Chemotherapy 98

Chemotherapy Biosimilars Labelling 98

pharmaphorum

AUGUST 31, 2022

Kaiku’s DPPM platform has also attracted the attention of other big pharma groups, including Roche which has been working with the company since 2019 on personalised support modules for patients taking its PD-L1 inhibitor Tecentriq (atezolizumab).

Chemotherapy 116

Chemotherapy Immunity Immunization Hospitals 116

Express Pharma

JULY 5, 2023

Venus Remedies has received marketing approvals from Oman, Malaysia, Bosnia and Trinidad and Tobago for key chemotherapy drugs. Pertinently, Malaysia, where the market size of cancer drugs was valued at $417 million in 2019, accounts for a sizeable revenue for Venus Remedies from the ASEAN region.

Chemotherapy 98

Chemotherapy 98

pharmaphorum

OCTOBER 19, 2020

MCL is generally treated first with chemotherapy, and patients whose disease progresses despite that can then receive stem cell transplantation or BTK inhibitor drugs like Johnson & Johnson/AbbVie’s Imbruvica (ibrutinib) and AstraZeneca’s Calquence (acalabrutinib).

Chemotherapy 124

Chemotherapy 124

pharmaphorum

AUGUST 4, 2021

The HDAC inhibitor was given an accelerated approval by the FDA as a second-line PTCL therapy on the strength of overall response data, but a phase 3 study comparing Istodax to first-line chemotherapy showed no improvement on progression-free survival (PFS).

Chemotherapy 98

Chemotherapy Labelling 98

STAT

JULY 24, 2023

Breast cancer has also shown an  accelerating increase  among women under 50, rising only slightly from 2000 to 2015 but increasing by 2 percent a year from 2015 to 2019. percent a year from 2017 to 2019; the yearly increase among women was 2.4 percent from 2000 to 2019.

Medical Schools 246

Medical Schools Hospitals Chemotherapy Immunity 246

pharmaphorum

MARCH 12, 2021

The UK Medicines and Healthcare products Regulatory Agency (MHRA) granted conditional approval for Retsevmo (selpercatinib) as monotherapy for adults with advance RET fusion-positive non-small cell lung cancer requiring systemic therapy after previous immunotherapy and/or chemotherapy treatment.

Chemotherapy 111

Chemotherapy Labelling 111

pharmaphorum

SEPTEMBER 29, 2021

Alexion teamed up with Caelum on CAEL-101 in 2019, taking a minority stake in the company, and the partners advanced the drug into the phase 3 CARES programme last year. Each year, an estimated 4,500 people develop AL amyloidosis in the US alone, and there are an estimated 30,000 to 45,000 people living with the disease in the US and Europe.

Chemotherapy 98

Chemotherapy 98

pharmaphorum

JUNE 6, 2022

Rozlytrek was approved by the FDA in 2019 but has just started to gather sales momentum, making around $17 million in the first quarter of this year, an increase of 78% on the first three months of 2021. Another research note from SVB Securities predicted that repotrectinib could eventually become a $1.5

Chemotherapy 98

Chemotherapy Labelling 98

pharmaphorum

FEBRUARY 15, 2021

To recap, Padcev (enfortumab vedotin) was quickly okayed by the FDA in December 2019 in advanced urothelial cancer on the basis of phase 2 response data that made it a rising star at that year’s American Society of Clinical Oncology (ASCO) conference. months in the chemotherapy group. of patients in the chemotherapy arm.

Chemotherapy 69

Chemotherapy 69

pharmaphorum

APRIL 19, 2022

The review will mainly look at AZ and Daiichi Sankyo’s DESTINY-Lung01, a phase 2 trial which showed a 55% overall response rate for Enhertu in patients previously treated with platinum chemotherapy, mainly partial responses, with a median duration of response of just over 9 months. billion licensing deal for the drug in 2019.

Chemotherapy 105

Chemotherapy 105

European Pharmaceutical Review

JULY 12, 2022

AstraZeneca’s blood-cancer treatment portfolio already includes Calquence (acalabrutinib), a chemotherapy-free monotherapy for patients with chronic lymphocytic leukaemia (CLL). . The transaction is expected to close in the third quarter of 2022, subject to customary closing conditions and regulatory clearances.

Immunity 98

Immunity Immunization Chemotherapy 98

STAT

MARCH 6, 2023

Still, when doctors told her last year that the cancer was growing despite two operations, radiation therapy, and a fifth regimen of chemotherapy, the retired business-meeting facilitator decided to do something unorthodox: spend $83,000 out of pocket on an unproven experimental cancer vaccine. Her husband said he had no regrets.

Vaccines 246

Vaccines Bioethics Immunization Immunity 246

pharmaphorum

JANUARY 18, 2021

Until now people with AL amyloidosis have had to rely on chemotherapy, with its accompanying side effects, and other drugs to tackle organ failure once damage gets severe. Darzalex Faspro looks set to transform the prospects for the 30,000 to 45,000 people in the US and Europe AL amyloidosis patients.

Chemotherapy 98

Chemotherapy 98

European Pharmaceutical Review

MAY 17, 2023

Novel device opens blood-brain barrier to deliver chemotherapy Intratumoural delivery The current trial was designed to evaluate the combination of intratumoural DNX-2401 followed by intravenous pembrolizumab therapy. The study enrolled 49 patients with recurrent GBM from several institutions between September 2016 to January 2019.

Immunization 98

Immunization Immunity Chemotherapy 98

pharmaphorum

DECEMBER 18, 2020

The drug was the first targeted at the mutation known as KRAS to show activity in the clinic and provided the biggest talking point at the American Society of Clinical Oncology (ASCO) conference in 2019.

Chemotherapy 98

Chemotherapy 98

pharmaphorum

MARCH 30, 2022

The SKYSCRAPER-02 showed that the combination of the two drugs given on top of chemotherapy was unable to improve progression-free survival versus Tecentriq (atezolizumab) plus chemo in extensive-stage SCLC – a notoriously hard-to-treat form of lung cancer.

Chemotherapy 97

Chemotherapy Immunity Immunization 97

RX Note

MARCH 31, 2025

Patients on chemotherapy, oral corticosteroids or drugs for HIV May be susceptible to more severe infection. 2019 Clinical Study on the Effectiveness of Three Products in the Treatment of Herpes Simplex Labialis, 2020 Cold sores located in the mouth or close to the eye Outside scope of community pharmacy.

Community Pharmacies 52

Community Pharmacies Chemotherapy 52

pharmaphorum

JANUARY 20, 2021

Sobi acquired Doptelet via its $915 million takeover of Dova Pharmaceuticals in 2019, adding to its haematology and rare disease franchise. The European approval of Doptelet as a second-line treatment for ITP after therapies such as corticosteroids and immunoglobulin drugs comes after a green light by the FDA in July 2019.

Chemotherapy 52

Chemotherapy Immunization Immunity 52

pharmaphorum

APRIL 27, 2021

Today (27 April), the ODAC is due to look at Tecentriq in combination with BMS/Celgene’s Abraxane (nab-paclitaxel) for people with advanced triple-negative breast cancer (TNBC) whose tumours express PD-L1, an indication which was provisionally approved by the FDA in 2019 on the strength of the Impassion130 study.

Chemotherapy 90

Chemotherapy Documentation Drug Development 90

Big Molecule Watch

MARCH 13, 2023

Udenyca (pegfilgrastim-cbqv) was first launched in the US in January 2019 and is one of six FDA approved pegfilgrastim biosimilars. Udenyca is administered the day after a chemotherapy treatment to decrease incidence of infection due to febrile neutropenia.

Biosimilars 52

Biosimilars Chemotherapy 52

pharmaphorum

DECEMBER 18, 2020

Margenza (margetuximab) won FDA approval in combination with chemotherapy to treat metastatic HER2-positive breast cancer after at least two previous rounds of therapy. The median progression-free survival (PFS) of patients treated with Margenza and chemotherapy was 5.8 months in patients treated with trastuzumab and chemotherapy.

Chemotherapy 52

Chemotherapy Biosimilars Immunity Immunization 52

pharmaphorum

AUGUST 11, 2021

. “This is welcome news for my patients, many of whom have already benefitted from the extra time this treatment gives them, without the need for chemotherapy,” said Dr Mark Verrill, a consultant medical oncologist at Newcastle upon Tyne Hospitals NHS Foundation Trust.

Chemotherapy 64

Chemotherapy Documentation Hospitals 64

Pharmaceutical Technology

MARCH 30, 2023

On March 27, MSD announced that the combined use of Keytruda with chemotherapy significantly improved progression-free survival versus the chemotherapy alone, as a first-line therapy for advanced or recurrent endometrial carcinoma. This announcement is not the only recent development for Keytruda.

Chemotherapy 52

Chemotherapy Packaging Documentation 52